# US 11,026,921 B2 · Compositions and methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,921 B2
- Document ID: US11026921B2
- Status: Granted
- Kind: B2
- Application number: 15/563,199
- Filed: 2016-03-30
- Published: 2018-03-29
- Granted: 2021-06-08
- Earliest claimed: 2015-03-30
- Assignees: Dana-Farber Cancer Institute, Inc.; Beth Israel Deaconess Medical Center, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.; Beth Israel Deaconess Medical Center
- Inventors: David Avigan; Jacalyn Rosenblatt; Donald Kufe
- Web page: https://patentgrep.com/patent/US11026921B2

## CPC

- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/09: having two or more such linkages
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 5/12: Fused cells, e.g. hybridomas
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides compositions and methods for treating cancer.

## Claims

### Claim 1

A method of treating a tumor in a patient comprising administering to said patient a composition comprising a population of autologous dendritic cell/tumor cell fusions (DC/tumor fusions) and an immunomodulatory agent, wherein the immunomodulatory agent is pomalidomide and/or apremilast.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor is a solid tumor.

### Claim 3 (depends on 2)

The method of claim 2, wherein said solid tumor is a breast tumor, or a renal tumor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tumor is a hematologic malignancy.

### Claim 5 (depends on 4)

The method of claim 4, wherein the hematologic malignancy is acute myeloid leukemia (AML) or multiple myeloma (MM).

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a checkpoint inhibitor.

### Claim 7 (depends on 6)

The method of claim 6, wherein the checkpoint inhibitor is administered one week after the DC/tumor fusions.

### Claim 8 (depends on 6)

The method of claim 6, wherein the checkpoint inhibitor is a PD1, PDL1, TIM3, or LAG3 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the further comprising administering an agent that targets regulatory T cells.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering said subject a TLR agonist or tetanus toxoid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the TLR agonist is CPG ODN or polylC.

### Claim 12 (depends on 4)

The method of claim 4, wherein the tumor is multiple myeloma and the patient has received an autologous stem cell transplant 30 to 100 days prior to the administration of the DC/tumor fusions.

### Claim 13 (depends on 5)

The method of claim 5, wherein the tumor is AML and the patient is in post chemotherapy induced remission of AML or with active AML disease.

### Claim 14 (depends on 2)

The method in claim 2, when the composition is administered following surgical resection of tumor for metastatic disease or as adjuvant therapy after removal of the primary tumor.

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient is treated with chemotherapy and the composition is administered 4 to 12 weeks following the completion of the chemotherapy.

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition comprises about 1×106 to 1×107DC/tumor fusions.